PMID- 35117287
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov
TI  - The efficacy and safety of immune checkpoint inhibitors combined with 
      antiangiogenic drugs in renal cell carcinomas: a systematic review and 
      meta-analysis.
PG  - 6780-6791
LID - 10.21037/tcr-20-1975 [doi]
AB  - BACKGROUND: The treatment of solid malignant tumors using immune checkpoint 
      inhibitors (ICIs) combined with antiangiogenic drugs, has gradually become an 
      active field of clinical research. However, the results are inconsistent. 
      Therefore, we designed this meta-analysis to evaluate the efficacy and safety of 
      ICIs combined with antiangiogenic drugs in patients with solid malignant tumors. 
      We found that the focus of combination therapy studies was on renal cell 
      carcinomas (RCC). METHODS: We searched PubMed, Embase, and the Cochrane Library 
      to summarize the hazard ratio (HR) for overall survival (OS), progression-free 
      survival (PFS), and the odds ratio (OR) for objective response rate (ORR), 
      disease control rate (DCR), and adverse events (AEs) of grade 3 or higher. 
      RESULTS: A total of 6 studies were included. We found that patients who received 
      antiangiogenic drugs combined with ICIs had better OS [HR =0.74, 95% confidence 
      interval (CI): 0.60-0.89], PFS (HR =0.79, 95% CI: 0.70-0.89), ORR (OR =2.34, 95% 
      CI: 1.35-4.04) and DCR (OR =1.52, 95% CI: 1.21-1.91) than those without ICIs. 
      There was no significant difference in the incidence of grade 3 or higher AEs (OR 
      =0.76, 95% CI: 0.52-1.11). Subgroup analyses showed that combination therapy 
      resulted in a lower risk of death in patients with PD-L1 expression >/=1% or <1%, 
      and better PFS in patients with RCCs who were of different ages, different 
      genders, and different International Metastatic Renal Cell Carcinoma Database 
      Consortium (IMDC) risk scores (favorable/intermediate/poor). CONCLUSIONS: The 
      results of this meta-analysis suggest that ICIs combined with antiangiogenic 
      drugs can provide more clinical benefits to patients with solid malignant tumors 
      without significantly increasing side effects. More clinical trials are needed to 
      validate these findings further.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - He, Qian
AU  - He Q
AD  - Department of Oncology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Li, Jiayi
AU  - Li J
AD  - Department of Oncology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Zhang, Chi
AU  - Zhang C
AD  - Department of Oncology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Tang, Sheng
AU  - Tang S
AD  - Department of Oncology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Ren, Qinglan
AU  - Ren Q
AD  - Department of Oncology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798721
OTO - NOTNLM
OT  - Immune checkpoint inhibitor (ICI)
OT  - angiogenesis inhibitor
OT  - immunotherapy
OT  - renal cell carcinomas (RCCs)
OT  - vascular endothelial growth factor (VEGF)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-20-1975). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/11/01 00:00
MHDA- 2020/11/01 00:01
PMCR- 2020/11/01
CRDT- 2022/02/04 05:50
PHST- 2020/05/01 00:00 [received]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2022/02/04 05:50 [entrez]
PHST- 2020/11/01 00:00 [pubmed]
PHST- 2020/11/01 00:01 [medline]
PHST- 2020/11/01 00:00 [pmc-release]
AID - tcr-09-11-6780 [pii]
AID - 10.21037/tcr-20-1975 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 Nov;9(11):6780-6791. doi: 10.21037/tcr-20-1975.